Comparative Pharmacology
Head-to-head clinical analysis: MIRCETTE versus VIORELE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIRCETTE versus VIORELE.
MIRCETTE vs VIORELE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and desogestrel; estrogen and progestin inhibit gonadotropin release, suppressing ovulation and altering cervical mucus and endometrial receptivity.
VIORELE is a monoclonal antibody that binds to and inhibits the activity of interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the pathogenesis of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
One tablet daily for 21 days, followed by 7 placebo tablets. Each active tablet contains 0.015 mg ethinyl estradiol and 2 mg chlormadinone acetate. Route: oral.
50 mg orally once daily
None Documented
None Documented
Desogestrel active metabolite etonogestrel: 21-24 hours; ethinyl estradiol: 12-14 hours
Terminal elimination half-life of 12–15 hours (mean 13.5 h) in healthy adults; may be prolonged in renal impairment (up to 30 h).
Urine (50-60% as metabolites, <10% unchanged), feces (30-40% as metabolites)
Primarily renal (unchanged drug and metabolites, ~60%) and fecal (~30%), with minor biliary contribution (~10%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive